A Novel Case of Bifacial Diplegia Variant of Guillain-Barré Syndrome Following Janssen COVID-19 Vaccination
Guillain-Barré syndrome (GBS) is an immune-mediated demyelinating disorder which attacks the peripheral nervous system. Antecedent infection or vaccine administration are known to precipitate the onset of this disorder. Its typical presentation leads to a symmetric, rapidly progressive, ascending p...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
MDPI AG,
2021-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_8a724a9290b94e81a31b12d4ab795289 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Apoorv Prasad |e author |
| 700 | 1 | 0 | |a Gage Hurlburt |e author |
| 700 | 1 | 0 | |a Sanjiti Podury |e author |
| 700 | 1 | 0 | |a Medha Tandon |e author |
| 700 | 1 | 0 | |a Seth Kingree |e author |
| 700 | 1 | 0 | |a Shitiz Sriwastava |e author |
| 245 | 0 | 0 | |a A Novel Case of Bifacial Diplegia Variant of Guillain-Barré Syndrome Following Janssen COVID-19 Vaccination |
| 260 | |b MDPI AG, |c 2021-08-01T00:00:00Z. | ||
| 500 | |a 10.3390/neurolint13030040 | ||
| 500 | |a 2035-8377 | ||
| 520 | |a Guillain-Barré syndrome (GBS) is an immune-mediated demyelinating disorder which attacks the peripheral nervous system. Antecedent infection or vaccine administration are known to precipitate the onset of this disorder. Its typical presentation leads to a symmetric, rapidly progressive, ascending paresis with associated sensory deficits and impaired reflexes. We present a rare case of a bi-facial diplegia variant of GBS, within four weeks of the COVID-19 vaccination. Due to its chronology, clinical manifestations, and cerebrospinal fluid (CSF) findings, we propose this case to be a rare complication of the COVID-19 vaccination. | ||
| 546 | |a EN | ||
| 690 | |a GBS | ||
| 690 | |a BFP | ||
| 690 | |a COVID-19 vaccine | ||
| 690 | |a SARS-CoV-2 | ||
| 690 | |a Medicine | ||
| 690 | |a R | ||
| 690 | |a Internal medicine | ||
| 690 | |a RC31-1245 | ||
| 690 | |a Neurosciences. Biological psychiatry. Neuropsychiatry | ||
| 690 | |a RC321-571 | ||
| 690 | |a Neurosciences. Biological psychiatry. Neuropsychiatry | ||
| 690 | |a RC321-571 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Neurology International, Vol 13, Iss 3, Pp 404-409 (2021) | |
| 787 | 0 | |n https://www.mdpi.com/2035-8377/13/3/40 | |
| 787 | 0 | |n https://doaj.org/toc/2035-8377 | |
| 856 | 4 | 1 | |u https://doaj.org/article/8a724a9290b94e81a31b12d4ab795289 |z Connect to this object online. |